Study register / Autonomic / Other / Psoriasis

Psoriasis

2 curated studies · 2 key studies · mechoulam.de

For psoriasis, only individual small studies exist. A controlled trial with cannabidiol oil showed no improvement in skin findings, though it did show relief of itching. Overall, the evidence is preliminary and insufficient for an assessment of benefit.

Rating scheme

The letter rates the quality of a study, independently of its type. Every study type can receive any grade: a review can be B or C when it is small or weak, and an RCT can be S. The grade is a synthesis of study design, journal authority and clinical bindingness:

S
Highest evidence, large, methodologically first-rate studies or S3 guidelines
A
Strong evidence, solid, meaningful studies with a clear result
B
Moderate evidence, smaller or methodologically limited studies
C
Weak evidence, preliminary, indirect or contradictory findings
D
Lowest evidence, exploratory hints, single cases or expert opinion

Quality profile per study

To the left of each study there is a profile of four features, it shows the differences within a letter class.

Sample size ★
Number of participants (RCT) or included studies (review).
Blinding
Double-blind, single-blind or open-label.
Effect size
Clear benefit, mixed, no benefit or harm.
Citations / year ★
Age-adjusted citation frequency.

Key studies

2
  1. 01
    B
    Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review.
    Kuzumi et al. ·2024 ·Experimental dermatology
    Read
  2. 02
    B
    Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial.
    Roongpisuthipong et al. ·2026 ·The Journal of dermatological treatment
    Read

Systematic Reviews and Meta-Analyses

Syntheses of RCT evidence following Cochrane and PRISMA standards.

1
B
Sample size ★★★★★
Blinding —
Effect size —
Citations / year —
● Key study
Kuzumi et al. ·2024 ·Experimental dermatology

Cannabinoids for the treatment of autoimmune and inflammatory skin diseases: A systematic review.

Design
Systematic Review
Sample
k = 15 Studien
Summary

Systematic review on cannabinoids in autoimmune and inflammatory skin diseases; k=15 clinical studies (SSc, DM, Psoriasis, AD) from 389 screened articles. Evidence suggests potential benefits for psoriasis and other indications, however further RCTs are needed. Mechanisms via the endocannabinoid system and anti-inflammatory properties are discussed.

DOI 10.1111/exd.15064 ↗

Randomised Controlled Trials

Efficacy and safety evidence from controlled interventional trials.

1
B
Sample size ★★★★★
Blinding Double-blind
Effect size No benefit
Citations / year ★★★★★
● Key study
Roongpisuthipong et al. ·2026 ·The Journal of dermatological treatment
0 citations

Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial.

Design
RCT
Sample
n = 28 Pat.
Key finding

CBD oil did not lead to a significant improvement in psoriasis severity (PASI scores), but showed temporary improvements in itch and sleep onset latency.

Summary

n=28 chronic plaque psoriasis, oral CBD oil 60 mg/day vs. placebo over 12 weeks. Primary outcome PASI score: no significant improvement. Secondary outcomes: significant itch reduction up to week 8, shortened sleep latency up to week 6 (not sustained). Adverse effects mild to moderate, comparable between groups.

DOI 10.1080/09546634.2025.2604448 ↗